Broad spectrum anti-HPV-L1 and E6/E7-IgY, small molecule antibody and application thereof

A HPV-L1, HPV-E6 technology, applied in the field of anti-broad-spectrum HPV-L1, E6/E7-IgY and its small molecule antibodies, can solve problems such as the lack of capsid protein expression, the failure of vaccines and therapeutic drugs, etc.

Pending Publication Date: 2019-07-26
SHENZHEN JASON INTELLIGENT BIOTECH CO LIMLTED PRC
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, for positive patients in the late stage of HPV infection, due to the integration of HPV virus DNA into the host cell DNA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Broad spectrum anti-HPV-L1 and E6/E7-IgY, small molecule antibody and application thereof
  • Broad spectrum anti-HPV-L1 and E6/E7-IgY, small molecule antibody and application thereof
  • Broad spectrum anti-HPV-L1 and E6/E7-IgY, small molecule antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0037] Specifically, the preparation method includes the following steps:

[0038] A. Preparation of broad-spectrum antigen:

[0039] The broad-spectrum antigens include preventive broad-spectrum HPV-L1 / L2-IgY antigens and therapeutic broad-spectrum or multivalent HPV-E6 / E7-IgY antigens, and the preventive broad-spectrum HPV-L1 / L2-IgY antigens include Fusion protein virus-like particle antigen, HPV31-L2 coupled KLH polypeptide antigen, HPV16-L2 or HPV18-L2 coupled KLH polypeptide antigen, L1 / L2 chimera pseudovirus VLP antigen, high-risk HPV L1 protein common antigen synthetic epitope polypeptide Antigen: The therapeutic broad-spectrum or multivalent HPV-E6 / E7-IgY antigen includes E6 / E7 fusion gene eukaryotic expression protein antigen, E6 / E7 fusion gene recombinant virus antigen, E6 / E7 protein common antigen synthetic epitope polypeptide Antigens: The preventive broad-spectrum HPV-L1 / L2 antigens and therapeutic broad-spectrum or multivalent HPV-E6 / E7 antigens also include a p...

Embodiment 1

[0260] Example 1: Anti-polyvalent HPV-E6 / E7 small-molecule antibody gel coupled with cell-penetrating peptides makes HPV positive women's "positive to negative" test

[0261] 1. General information and methods

[0262] 1.1 General information

[0263] 1.1.1 Selection criteria

[0264] (1) aged between 25 and 50 years old, with a history of sexual life; (2) cervical cancer screening TCT (-), HPV (-) within 3 years; (2) cervical cancer screening TCT (-), High-risk HPV-any one of 15 types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) to multiple types (+).

[0265] 1.1.2 Exclusion criteria

[0266] (1) History of cervical cancer and precancerous lesions in the past; (2) HPV (+) in the past; (3) High-risk HPV-15 types (16, 18, 31, 33, 35, 39) in this cervical cancer screening , 45, 51, 52, 56, 58, 59, 68, 73, 82) other HPV types (+); (4) history of hysterectomy; (5) current pregnancy; (6) patients without follow-up conditions.

[0267] A total of 96 women...

Embodiment 2

[0280] Example 2: Preparation of liposome liquid crystal microcapsules coupled with cell-penetrating peptide anti-multivalent HPV-E6 / E7 small molecule antibodies.

[0281] The specific implementation steps are as follows:

[0282] (1) Dissolve 50% of lecithin and cholesterol in ether in a ratio of 1:5;

[0283] (2) Add the prepared dry powder of coupled cell-penetrating peptide anti-multivalent HPV-E6 / E7 small molecule antibody at a ratio of 1:100 to 4mmol / L phosphate buffer saline (PBS) to make a small molecule with a concentration of 1%. Antibody solution;

[0284] (3) Mix the lecithin and cholesterol ether solution with the PBS solution of the small molecule antibody in a ratio of 3:1;

[0285] (4) Ultrasonic treatment for 2 minutes (0.5 minutes per treatment, 0.5 minutes intermittently);

[0286] (5) Evaporate under reduced pressure in a water bath until it becomes a gel, vortex to invert the phase of the gel, and then continue to evaporate to remove the ether;

[0287...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses broad spectrum or multivalent anti-HPV-L1 and E6/E7-IgY, a small molecule antibody, a preparation method, a composition and application thereof. The genetic recombination technology is adopted to prepare prophylactic broad spectrum anti-HPV-L1-IgY and therapeutic broad spectrum or multivalent anti-HPV-E6/E7-IgY and the small molecule antibody, and the broad spectrum or multivalent anti-HPV small molecule antibody is subjected to long-term modification with liposomes and cell penetrating peptides coupled. The invention also provides a liquid crystal microcapsule, a gel,a suppository, a cream, a lotion, a tablet, an effervescent tablet, a capsule, a soft capsule and an injection prepared by the broad spectrum or multivalent anti-HPV-IgY, the small molecule antibody and the composition, as well as the application in drugs, disinfectants, health products and medical devices for prevention and treatment of human papillomavirus (HPV) infections. The majority of HPV infections can be prevented, and HPV-infected positive patients can be treated to achieve the positive-to-negative conversion effect.

Description

technical field [0001] The invention relates to the field of biotechnology, more specifically, relates to an anti-broad-spectrum HPV-L1, E6 / E7-IgY and small molecule antibody, composition, preparation method and application thereof. Background technique [0002] Cervical cancer is a disease that seriously endangers women's health and life. Every 2 minutes in the world, one person dies from cervical cancer. Modern medicine has proved that cervical cancer is caused by a human papillomavirus (HPV) infection, the proportion of which is as high as 80%. The total number reached about 630 million people, accounting for 10% of the total population. According to a survey of the National Health and Nutrition Research Project from the United States in 2003-2004, the total HPV infection rate of 14-59 years old in various countries in the world is as high as 26.8%. It can be seen that the harm caused by HPV infection to women around the world far exceeds previous estimate. [0003] At...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/08C07K16/02C12P21/06A61K39/395A61K47/64A61K9/127A61P31/20
CPCC07K16/084C07K16/02C12P21/06A61K39/39533A61K47/64A61K9/1274A61K9/1277A61P31/20C07K2317/31C07K2317/35
Inventor 包晟杨荣鉴王长安曹天福龚芹
Owner SHENZHEN JASON INTELLIGENT BIOTECH CO LIMLTED PRC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap